Compare SLNG & ORMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLNG | ORMP |
|---|---|---|
| Founded | 2013 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 119.0M | 170.3M |
| IPO Year | 2019 | 2010 |
| Metric | SLNG | ORMP |
|---|---|---|
| Price | $5.14 | $4.69 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | 39.0K | ★ 198.5K |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | ★ 6.51% |
| EPS Growth | ★ 2400.00 | 412.50 |
| EPS | N/A | ★ 2.76 |
| Revenue | ★ $68,245,000.00 | $2,000,000.00 |
| Revenue This Year | $8.66 | N/A |
| Revenue Next Year | $14.31 | N/A |
| P/E Ratio | ★ N/A | $1.68 |
| Revenue Growth | N/A | ★ 49.25 |
| 52 Week Low | $3.21 | $2.09 |
| 52 Week High | $7.07 | $5.47 |
| Indicator | SLNG | ORMP |
|---|---|---|
| Relative Strength Index (RSI) | 40.84 | 46.12 |
| Support Level | $4.27 | $3.91 |
| Resistance Level | $5.61 | $5.10 |
| Average True Range (ATR) | 0.50 | 0.20 |
| MACD | -0.17 | -0.07 |
| Stochastic Oscillator | 5.80 | 8.70 |
Stabilis Solutions Inc is an energy transition company that provides turnkey clean energy production, storage, transportation, and fueling solutions using liquefied natural gas (LNG) to multiple end markets. The company provides LNG solutions to customers in diverse end markets, including aerospace, agriculture, energy, industrials, marine bunkering, mining, pipeline, remote power, and utility markets. It generates revenue by selling and delivering LNG to its customers, renting cryogenic equipment, and providing engineering and field support services. The company has a geographical presence in the United States and Mexico.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.